NASDAQ:ALZN Alzamend Neuro (ALZN) Stock Price, News & Analysis $1.12 -0.01 (-0.80%) As of 10:53 AM Eastern This is a fair market value price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsInsider TradesNews and TrendsOwnershipSEC Filings About Alzamend Neuro Stock (NASDAQ:ALZN) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Alzamend Neuro alerts:Sign Up Key Stats Today's Range$1.14▼$1.1650-Day Range$1.12▼$1.9452-Week Range$0.84▼$2.68Volume841 shsAverage Volume117,918 shsMarket Capitalization$5.41 millionP/E RatioN/ADividend YieldN/APrice Target$28.00Consensus RatingHold Company Overview Alzamend Neuro, Inc. (NASDAQ: ALZN) is a clinical-stage biopharmaceutical company focused on developing treatments for neurodegenerative and neuropsychiatric diseases, with an emphasis on Alzheimer’s disease and related dementia. The company’s research is intended to address cognitive decline and other disease-related symptoms through therapies designed to affect biological processes associated with brain function. Alzamend Neuro’s lead development program is AL001, an investigational lithium-based product candidate being studied for potential use in the treatment of Alzheimer’s disease. The company is also advancing AL002, an additional investigational product candidate intended to address Alzheimer’s disease through a different therapeutic approach. These candidates remain in development and have not been approved for commercial use. The company was established to pursue pharmaceutical technologies for central nervous system disorders and is conducting its development activities through clinical research and collaborations. As a development-stage biotechnology company, Alzamend Neuro does not currently have an established portfolio of commercially marketed products. Information about its operations and clinical programs is primarily provided through its public regulatory filings and corporate disclosures.AI Generated. May Contain Errors. Read More Alzamend Neuro Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks72nd Percentile Overall ScoreALZN MarketRank™: 3.623305141625 of 5 starsAlzamend Neuro scored higher than 72% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.2 / 5Analyst RatingHold Consensus RatingAlzamend Neuro has received a consensus rating of Hold. The company's average rating score is 2.00, and is based on no strong buy ratings, 1 buy rating, no hold ratings, and 1 sell rating.Upside PotentialAlzamend Neuro has a consensus price target of $28.00, representing about 2,377.9% upside from its current price of $1.13.Amount of Analyst CoverageAlzamend Neuro has only been the subject of 1 research reports in the past 90 days.Read more about Alzamend Neuro's stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for Alzamend Neuro are expected to grow in the coming year, from ($1.05) to ($0.87) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Alzamend Neuro is -0.49, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Alzamend Neuro is -0.49, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Read more about Alzamend Neuro's valuation and earnings. Short Interest5.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted0.72% of the float of Alzamend Neuro has been sold short.Short Interest Ratio / Days to CoverAlzamend Neuro has a short interest ratio ("days to cover") of 0.68, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Alzamend Neuro has recently decreased by 69.36%, indicating that investor sentiment is improving significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldAlzamend Neuro does not currently pay a dividend.Dividend GrowthAlzamend Neuro does not have a long track record of dividend growth. News and Social Media3.4 / 5News Sentiment1.39 News SentimentAlzamend Neuro has a news sentiment score of 1.39. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.69 average news sentiment score of Healthcare companies.News Coverage This WeekMarketBeat has tracked 2 news articles for Alzamend Neuro this week, compared to 2 articles on an average week.Search InterestOnly 1 people have searched for ALZN on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days.MarketBeat Follows2 people have added Alzamend Neuro to their MarketBeat watchlist in the last 30 days. Company Ownership1.4 / 5Insider TradingSelling Shares Insider Buying vs. Insider SellingIn the past three months, Alzamend Neuro insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $3,120.00 in company stock.Percentage Held by Insiders1.39% of the stock of Alzamend Neuro is held by insiders.Percentage Held by Institutions49.61% of the stock of Alzamend Neuro is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Alzamend Neuro's insider trading history. Receive ALZN Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Alzamend Neuro and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. ALZN Stock News HeadlinesAlzamend Neuro Highlights Early AL001 Brain Lithium DataSeptember 29, 2026 | tipranks.comAlzamend Regains Compliance With Nasdaq Equity RequirementSeptember 17, 2026 | rttnews.comFederal Reserve Reveals Disturbing New Plan To Control Your MoneyDocket No. OP-1670 is drawing attention for what it reveals about the Federal Reserve's next move. Buried on page 84 is a plan that could expand oversight of checking accounts, purchases, and money transfers across the country. Martin D. Weiss, PhD, founder of Weiss Ratings, breaks down what this document means and why it could roll out as soon as this summer.October 28 at 1:00 AM | Weiss Ratings (Ad)Alzamend Neuro's Phase 1/2A Lithium Neuroimaging Data Accepted for Poster Presentation at Neuroscience 2026 in Washington, DCAugust 20, 2026 | prnewswire.comAlzamend Neuro's Phase 1/2A Lithium Imaging Data Accepted for Oral Presentation at ISMRM Workshop on X-Nuclei MR in Barcelona, SpainAugust 18, 2026 | prnewswire.comAlzamend Neuro Announces Initial Closing of Securities Purchase Agreement with Ault LendingAugust 4, 2026 | prnewswire.comAlzamend Neuro’s AL001 Lithium Study Reaches Completion, Setting Up Next Clinical StepsJuly 29, 2026 | tipranks.comAlzamend Neuro’s New Lithium Study Puts AL001 in the Bipolar Disorder SpotlightJuly 28, 2026 | tipranks.comSee More Headlines ALZN Stock Analysis - Frequently Asked Questions How have ALZN shares performed this year? Alzamend Neuro's stock was trading at $1.82 at the start of the year. Since then, ALZN shares have decreased by 37.9% and is now trading at $1.13. How were Alzamend Neuro's earnings last quarter? Alzamend Neuro, Inc. (NASDAQ:ALZN) posted its quarterly earnings data on Thursday, September, 10th. The company reported ($0.68) earnings per share for the quarter, missing analysts' consensus estimates of ($0.56) by $0.12. When did Alzamend Neuro's stock split? Alzamend Neuro's stock reverse split on Tuesday, July 16th 2024.The 1-10 reverse split was announced on Tuesday, July 16th 2024. The number of shares owned by shareholders was adjusted after the closing bell on Tuesday, July 16th 2024. An investor that had 100 shares of stock prior to the reverse split would have 10 shares after the split. When did Alzamend Neuro IPO? Alzamend Neuro (ALZN) raised $12 million in an initial public offering on the week of June 14th 2021. The company issued 2,500,000 shares at a price of $5.00 per share. Spartan Capital Securities, LLC served as the underwriter for the IPO and -- was co-manager. How do I buy shares of Alzamend Neuro? Shares of ALZN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Alzamend Neuro own? Based on aggregate information from My MarketBeat watchlists, some other companies that Alzamend Neuro investors own include Tesla (TSLA), Ford Motor (F), NIO (NIO), Advanced Micro Devices (AMD), NVIDIA (NVDA), Aurora Cannabis (ACB) and Bollinger Innovations (BINI). Company Calendar Last Earnings9/10/2026Today10/28/2026Next Earnings (Estimated)12/08/2026Fiscal Year End4/30/2027Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Green Zone (2m+) 1-Year History Oct 25 Jan 26 Apr 26 Jul 26 Oct 26 ALZN's financial health is in the Green zone, according to TradeSmith. ALZN has been in this zone for over 2 months. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Biotechnology Sub-IndustryBiotechnology Current SymbolNASDAQ:ALZN CIK1677077 Webwww.alzamend.com Phone(844) 722-6333FaxN/AEmployees6Year FoundedN/APrice Target and Rating Average Price Target for Alzamend Neuro$28.00 High Price Target$28.00 Low Price Target$28.00 Potential Upside/Downside+2,356.1%Consensus RatingHold Rating Score (0-4)2.00 Research Coverage2 Analysts Profitability EPS (Trailing Twelve Months)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book ValueN/A Price / BookN/AMiscellaneous Outstanding Shares4,826,000Free Float4,759,000Market Cap$5.50 million OptionableNo Data Beta0.27 The Infrastructure's Backbone: 10 Stocks Powering the AI BuildoutThe AI boom extends far beyond the biggest tech names. Discover 10 companies supplying the memory, storage, networking, semiconductor manufacturing, and power infrastructure that make AI possible. Learn where the next wave of AI investment opportunities may emerge—and the key risks investors should watch as the global AI buildout accelerates.Get This Free Report This page (NASDAQ:ALZN) was last updated on 10/28/2026 by MarketBeat.com Staff. From Our PartnersFinancial legend: “This is bad, really bad...”Dr. Martin D. Weiss has publicly predicted six major American market crashes over his 55-year career, each war...Weiss Ratings | SponsoredElon Musk’s One Stock Retirement PlanStanley Druckenmiller once said you don't get rich diversifying into 50 mediocre assets - you get rich finding...Brownstone Research | Sponsored80 Days Until America's Rare Earth Supply Chain ShiftChina controls more than 90% of global rare earth alloy production, leverage it is using to restrict exports t...The Tomorrow Investor | SponsoredMy next big call (under $1)17,556% on KDA. 3,900% on PRE. 2,650% on OCEAN. Every single one of these was recommended to our community bef...Crypto 101 Media | SponsoredBezos… DOOMED?A single FCC filing hints Elon Musk is planning his biggest project yet - bigger than Tesla, SpaceX, and X com...Paradigm Press | SponsoredThe chip inside every TeslaEvery Tesla built since 2012 pays this small, overlooked supplier a fee for its technology. So does every Star...Behind the Markets | SponsoredAnd they say the headline number understates what’s really happening.Goldman Sachs just admitted it underestimated central bank gold purchases by more than 500 percent, with buyin...Cedar Gold Group | SponsoredExecutive Order 14241 Unleashes Trump’s New DollarA landmark executive order, 14241, is reportedly set to reshape how Americans use money starting this December...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Alzamend Neuro, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Alzamend Neuro With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
